AllSci News
Ipsen hopeful for corabotase as Botox alternative after positive Phase II
Ipsen (Euronext: IPN; ADR: IPSEY) reported Phase II data for corabotase in moderate-to-severe glabellar lines showing that 60.8% of patients maintained a...
Novartis posts data for Pluvicto in indication-expanding prostate cancer trial
Novartis (SWX: NOVN) reported new data from the Phase III PSMAddition trial showing that lutetium (177Lu) vipivotide tetraxetan (Pluvicto) reduced the risk...
FDA approves first interchangeable Simponi biosimilars
The US FDA has approved Immgolis and Immgolis Intri (golimumab-sldi) as the first interchangeable biosimilars to Johnson & Johnson’s Simponi and Simponi…
Canadian researchers identify naporafenib-trametinib combo strategy for anaplastic thyroid cancer
Researchers at Western University and London Health Sciences Centre in London, Ontario, Canada, working with collaborators at the Ontario Institute for...
Quince acquires Orphai for inhaled mTOR inhibitor, raises USD 187m
Quince Therapeutics (Nasdaq: QNCX), based in South San Francisco, has acquired Orphai Therapeutics Inc., a private clinical-stage company, in a...
Merck partners with China's Degron, Medimscience on molecular glue, autoimmune programs
Merck (NYSE: MRK) has signed two clinical collaboration agreements and two memorandums of understanding with Chinese biotech companies through its MSD R&D...
Context Therapeutics pays USD 6.5m to buy out BioAtla CT-202 Nectin-4 CD3 obligations
Context Therapeutics (Nasdaq: CNTX) has paid USD 6.5 million to buy out all future milestone and royalty obligations on CT-202, its Nectin-4 x CD3 T cell...
Neurocrine completes USD 2.9b acquisition of Soleno for rare disease portfolio expansion
Neurocrine Biosciences (Nasdaq: NBIX) has completed its acquisition of Soleno Therapeutics for a total equity value of USD 2.9 billion, adding VYKAT XR...
BioMarin faces uncertainty for ENPP1 enzyme replacement therapy after mixed Phase III
BioMarin Pharmaceutical (Nasdaq: BMRN) reported that its Phase III ENERGY 3 trial evaluating BMN 401 in children aged 1 to 12 with ENPP1 deficiency met only...
Biotheryx's CDK4/6 degrader produces 80% clinical benefit in Phase I breast cancer trial
Biotheryx reported Phase I dose escalation data for BTX-9341, a first-in-class oral CDK4/6 bifunctional degrader, showing a clinical benefit rate of 80% in...
Vincentage Pharma's oral GLP-1 achieves 12% weight loss in China Phase III
Vincentage Pharma, a Chengdu-based metabolic disease company, reported that VCT220, its oral small-molecule GLP-1 receptor agonist, produced mean body...
Merck posts first positive Phase III data for TROP2 ADC sacituzumab tirumotecan in endometrial cancer
Merck (NYSE: MRK) reported that sacituzumab tirumotecan endometrial cancer data from the Phase III TroFuse-005 trial met both co-primary endpoints of...
AstraZeneca’s Baxfendy becomes first aldosterone synthase inhibitor approved for hypertension in US
AstraZeneca (LSE/STO/NYSE: AZN) has received US FDA approval for Baxfendy (baxdrostat), making it the first aldosterone synthase inhibitor cleared for the treatment…
Genentech's Tecentriq gets FDA nod as adjuvant for muscle-invasive bladder cancer treatment
Genentech has secured an atezolizumab bladder cancer FDA approval for the adjuvant treatment of muscle-invasive bladder cancer, with the US FDA clearing...
Regeneron and Parabilis strike USD 2.325b deal for antibody-Helicon conjugate therapeutics
Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a research collaboration with private Cambridge, Massachusetts-based Parabilis Medicines to discover...
The AllSci Brief
Systematic R&D and deal news. Daily.